Evidence map›Paper›PMID 33995661›Full record

ReviewTheranostics2021

Multifunctional nanoplatforms co-delivering combinatorial dual-drug for eliminating cancer multidrug resistance.

Xiao Wei, Mingzhu Song, Weijie Li, Jing Huang, Guang Yang, Yi Wang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Theranostics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiao WeiSchool of Preclinical Medicine, Chengdu University, Chengdu 610106, P. R. China.
Mingzhu SongSchool of Preclinical Medicine, Chengdu University, Chengdu 610106, P. R. China.
Weijie LiSchool of Preclinical Medicine, Chengdu University, Chengdu 610106, P. R. China.
Jing HuangSchool of Preclinical Medicine, Chengdu University, Chengdu 610106, P. R. China.
Guang YangCollege of Medicine, Southwest Jiaotong University, Chengdu 610031, P. R. China.
Yi WangSchool of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, P. R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinically, the primary cause of chemotherapy failure belongs to the occurrence of cancer multidrug resistance (MDR), which directly leads to the recurrence and metastasis of cancer along with high mortality. More and more attention has been paid to multifunctional nanoplatform-based dual-therapeutic combination to eliminate resistant cancers. In addition to helping both cargoes improve hydrophobicity and pharmacokinetic properties, increase bioavailability, release on demand and enhance therapeutic efficacy with low toxic effects, these smart co-delivery nanocarriers can even overcome drug resistance. Here, this review will not only present different types of co-delivery nanocarriers, but also summarize targeted and stimuli-responsive combination nanomedicines. Furthermore, we will focus on the recent progress in the co-delivery of dual-drug using such intelligent nanocarriers for surmounting cancer MDR. Whereas it remains to be seriously considered that there are some knotty issues in the fight against MDR of cancers via using co-delivery nanoplatforms, including limited intratumoral retention, the possible changes of combinatorial ratio under complex biological environments, drug release sequence from the nanocarriers, and subsequent free-drug resistance after detachment from the nanocarriers. It is hoped that, with the advantage of continuously developing nanomaterials, two personalized therapeutic agents in combination can be better exploited to achieve the goal of cooperatively combating cancer MDR, thus advancing the time to clinical transformation.

Indexed as

Drug Delivery SystemsAntineoplastic Combined Chemotherapy ProtocolsApoptosisATP-Binding Cassette TransportersATP Binding Cassette Transporter, Subfamily BDoxorubicinDrug CarriersDrug LiberationDrug Resistance, MultipleDrug Resistance, NeoplasmGasesHumansHydrogen-Ion ConcentrationNanostructuresNeoplasm ProteinsOxidation-ReductionATP-Binding Cassette TransportersATP Binding Cassette Transporter, Subfamily BDoxorubicinDrug CarriersGasesNeoplasm ProteinsPeptidesRNA, Small InterferingSurface-Active Agentscancer therapyco-deliverydual-drugmultidrug resistancemultifunctional nanoplatform

Identifiers

PMID33995661
PMCPMC8120214

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.